Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 1
1995 2
1996 2
1998 2
2000 1
2002 1
2003 1
2006 1
2007 2
2008 2
2009 1
2010 2
2011 4
2012 4
2013 4
2014 2
2015 3
2016 2
2017 5
2018 6
2019 7
2020 6
2021 7
2022 8
2023 3
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

75 results

Results by year

Filters applied: . Clear all
Page 1
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. Narayan V, et al. Among authors: farwell md. Nat Med. 2022 Apr;28(4):724-734. doi: 10.1038/s41591-022-01726-1. Epub 2022 Mar 21. Nat Med. 2022. PMID: 35314843 Free PMC article. Clinical Trial.
Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74.
Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, Liousia M, Lohith K, Xu K, Edwards KJ, Farwell MD, June CH, Albelda SM, Puré E, Sellmyer MA. Lee IK, et al. Among authors: farwell md. Clin Cancer Res. 2022 Dec 15;28(24):5330-5342. doi: 10.1158/1078-0432.CCR-22-1379. Clin Cancer Res. 2022. PMID: 35972732 Free PMC article.
Immune PET Imaging.
Iyalomhe O, Farwell MD. Iyalomhe O, et al. Among authors: farwell md. Radiol Clin North Am. 2021 Sep;59(5):875-886. doi: 10.1016/j.rcl.2021.05.010. Radiol Clin North Am. 2021. PMID: 34392924 Free PMC article. Review.
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC. Huang AC, et al. Among authors: farwell md. Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25. Nat Med. 2019. PMID: 30804515 Free PMC article. Clinical Trial.
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody.
Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, Mascioni A, Le W, Wilson I, Gordon MS, Wu AM, Ulaner GA, Wolchok JD, Postow MA, Pandit-Taskar N. Farwell MD, et al. J Nucl Med. 2022 May;63(5):720-726. doi: 10.2967/jnumed.121.262485. Epub 2021 Aug 19. J Nucl Med. 2022. PMID: 34413145 Free PMC article. Clinical Trial.
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S, Nandi A, Anderson S, Han N, Manne S, Kiner E, Sachar C, Lucas M, George S, Yan PK, Kier MW, Laughlin AI, Kothari S, Giles J, Mathew D, Ghinnagow R, Alanio C, Flowers A, Xu W, Tenney DJ, Xu X, Amaravadi RK, Karakousis GC, Schuchter LM, Buggert M, Oldridge D, Minn AJ, Blank C, Weber JS, Mitchell TC, Farwell MD, Herati RS, Huang AC. Wang K, et al. Among authors: farwell md. Cancer Cell. 2024 Sep 9;42(9):1582-1597.e10. doi: 10.1016/j.ccell.2024.08.007. Epub 2024 Aug 29. Cancer Cell. 2024. PMID: 39214097
Artificial intelligence in immunotherapy PET/SPECT imaging.
McGale JP, Chen DL, Trebeschi S, Farwell MD, Wu AM, Cutler CS, Schwartz LH, Dercle L. McGale JP, et al. Among authors: farwell md. Eur Radiol. 2024 Sep;34(9):5829-5841. doi: 10.1007/s00330-024-10637-3. Epub 2024 Feb 15. Eur Radiol. 2024. PMID: 38355986 Review.
Development of Companion Diagnostics.
Mankoff DA, Edmonds CE, Farwell MD, Pryma DA. Mankoff DA, et al. Among authors: farwell md. Semin Nucl Med. 2016 Jan;46(1):47-56. doi: 10.1053/j.semnuclmed.2015.09.002. Semin Nucl Med. 2016. PMID: 26687857 Free PMC article. Review.
Positron Emission Tomography.
Lameka K, Farwell MD, Ichise M. Lameka K, et al. Among authors: farwell md. Handb Clin Neurol. 2016;135:209-227. doi: 10.1016/B978-0-444-53485-9.00011-8. Handb Clin Neurol. 2016. PMID: 27432667 Review.
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.
Shankar LK, Schöder H, Sharon E, Wolchok J, Knopp MV, Wahl RL, Ellingson BM, Hall NC, Yaffe MJ, Towbin AJ, Farwell MD, Pryma D, Poussaint TY, Wright CL, Schwartz L, Harisinghani M, Mahmood U, Wu AM, Leung D, de Vries EGE, Tang Y, Beach G, Reeves SA. Shankar LK, et al. Among authors: farwell md. Lancet Oncol. 2023 Mar;24(3):e133-e143. doi: 10.1016/S1470-2045(22)00742-2. Lancet Oncol. 2023. PMID: 36858729 Free PMC article. Review.
75 results